home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

425.28 +5.90 (+1.41%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

70 71 Next >

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead ↗

February 05, 2025

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Via Benzinga

Topics Earnings

Amgen Options Trading: A Deep Dive into Market Sentiment ↗

February 05, 2025

Via Benzinga

Earnings Miss? Amgen’s Dividend Still a Bright Spot

February 05, 2025

Via MarketBeat

Amgen (AMGN) Q4 2024 Earnings Call Transcript ↗

February 05, 2025

AMGN earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Amgen Surpasses Q4 Earnings Forecasts ↗

February 04, 2025

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Via The Motley Fool

Earnings Summary: Amgen Q4 ↗

February 04, 2025

Via Benzinga

Amgen Beat Fourth-Quarter Expectations. So, Why Did Shares Tumble? ↗

February 04, 2025

In after-hours trades, Amgen stock fell around 2% following its fourth-quarter beat.

Via Investor's Business Daily

Analyst Expectations For Amgen's Future ↗

January 28, 2025

Via Benzinga

This Is What Whales Are Betting On Amgen ↗

January 27, 2025

Via Benzinga

Amgen’s (NASDAQ:AMGN) Q4 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations

February 04, 2025

Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 10.9% year on year to $9.09 billion. The company’s full-year revenue guidance of...

Via StockStory

These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025 ↗

February 04, 2025

Via The Motley Fool

Topics Stocks

Markets React To Softening Trade Tariff Policy ↗

February 04, 2025

Monday’s trading session resulted in slight negative closes across major indexes, but there’s good news here: whereas the Dow finished the trading day -122 points, it was -400 a half hour before this...

Via Talk Markets

Topics Stocks Stocks / Equities

The Dogs Of The Dow 2025 ↗

January 31, 2025

The Dogs of the Dow is an investing strategy well-known to retail and institutional investors.

Via Talk Markets

Topics Stocks Stocks / Equities

Unpacking the Latest Options Trading Trends in Amgen ↗

January 13, 2025

Via Benzinga

Peering Into Amgen's Recent Short Interest ↗

January 13, 2025

Via Benzinga

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday? ↗

February 04, 2025

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.

Via Benzinga

Earnings Scheduled For February 4, 2025 ↗

February 04, 2025

Via Benzinga

Friday's pre-market session: top gainers and losers in the S&P500 index ↗

January 31, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 ↗

January 25, 2025

Via The Motley Fool

Topics Stocks

Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results ↗

January 24, 2025

The Danish drug giant reported a 22% weight loss over 36 weeks.

Via Investor's Business Daily

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗

January 21, 2025

Via The Motley Fool

Topics Stocks

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation ↗

January 17, 2025

Amgen's Lumakras treatment, combined with Vectibix, is FDA-approved for KRAS G12C-mutated colorectal cancer.

Via Benzinga

2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows ↗

January 16, 2025

Via The Motley Fool

What Lies Ahead In 2025? Slower Growth, More Volatility ↗

January 14, 2025

As we move through 2025, the global economy and financial markets are facing a critical juncture.

Via Talk Markets

Topics Economy Stocks / Equities

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows. ↗

January 14, 2025

Via The Motley Fool

3 High-Yield Dividend Stocks to Buy in 2025 ↗

January 13, 2025

Via The Motley Fool

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

70 71 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com